citalopram has been researched along with Multiple Sclerosis, Relapsing-Remitting in 4 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bermel, RA | 1 |
| Hashmonay, R | 1 |
| Meng, X | 1 |
| Randhawa, S | 1 |
| von Rosenstiel, P | 1 |
| Sfikas, N | 1 |
| Kantor, D | 1 |
| Mitsonis, CI | 1 |
| Zervas, IM | 1 |
| Potagas, CM | 1 |
| Mitropoulos, PA | 1 |
| Dimopoulos, NP | 1 |
| Sfagos, CA | 1 |
| Papadimitriou, GN | 1 |
| Vassilopoulos, DC | 1 |
| Stucke, K | 1 |
| Kieser, M | 1 |
| Pandya, R | 1 |
| Patten, S | 1 |
1 trial available for citalopram and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study.
Topics: Adolescent; Adult; Citalopram; Female; Humans; Life Change Events; Multiple Sclerosis, Relapsing-Rem | 2010 |
3 other studies available for citalopram and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.
Topics: Adult; Citalopram; Clinical Trials as Topic; Drug Therapy, Combination; Electrocardiography; Female; | 2015 |
A general approach for sample size calculation for the three-arm 'gold standard' non-inferiority design.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Lik | 2012 |
Depression in multiple sclerosis associated with interferon beta-1a (Rebif).
Topics: Adjuvants, Immunologic; Adult; Citalopram; Depressive Disorder; Female; Humans; Interferon beta-1a; | 2002 |